Biotherapy

, Volume 4, Issue 1, pp 45–52 | Cite as

Inhibiting tissue invasion and metastasis as targets for cancer therapy

  • M. J. Duffy
Article

Abstract

Many of the steps involved in cancer spread are potential targets for anti-metastatic treatment. Until recently, research aimed at inhibiting metastasis has concentrated on the proteases, especially on urokinase-type plasminogen activator and collagenase IV However, recent data suggests that both adhesion proteins and motility factors could also serve as targets for new treatments to prevent cancer invasion and metastasis. Almost all the work to date using anti-metastatic agents has been carried out using either in vitro artificial membranes or with animal models. It is, however, likely that some of the inhibitors of experimental metastasis which are described will be evaluated in clinical trials in the near future.

Key words

cancer invasiveness metastasis plasminogen activator proteases 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schirrmacher V. Cancer metastasis: experimental approaches, theoretical concepts and impact for treatment strategies. Adv Cancer Res 1985; 43: 1–73.PubMedGoogle Scholar
  2. 2.
    Tarin D. Clinical and experimental studies on the biology of metastasis. Biochim Biophys Acta 1985; 780: 227–35.PubMedGoogle Scholar
  3. 3.
    Tryggvason K, Hayhtya M, Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 1987; 907: 191–217.PubMedGoogle Scholar
  4. 4.
    Timpl R. Structure and biological activity of basement membrane proteins. Eur J Biochem 1989; 180: 487–502.PubMedGoogle Scholar
  5. 5.
    Liotta L, Kohn E. Cancer invasion and metastasis. JAMA 1990; 263: 1123–6.PubMedGoogle Scholar
  6. 6.
    Ruoslahti E, Pierschbacher M. New perspectives in cell adhesion: RGD and integrins. Science 1987; 238: 491–7.PubMedGoogle Scholar
  7. 7.
    Akiyama SK, Nagata K, Yamada K. Cell surface receptors for extracellular matrix components. Biochim Biophys Acta 1990; 1031: 91–110.PubMedGoogle Scholar
  8. 8.
    Wewer UM, Tarabolletti G, Sobel ME, Albrechtsen R, Liotta L. Laminin receptor: role in tumor cell migration. Cancer Res 1987; 47: 5691–8.PubMedGoogle Scholar
  9. 9.
    Pierschbacher M, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984; 309: 30–3.PubMedGoogle Scholar
  10. 10.
    Dedhar S, Ruoslahti E, Perschbacher M. A cell surface receptor complex for collagen type 1 recognizes the Arg-Gly-Asp sequence. J Cell Biol 1987; 104: 585–93.PubMedGoogle Scholar
  11. 11.
    Iwamoto Y, Robey FA, Graf J et al. YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science 1987; 238: 1132–4.PubMedGoogle Scholar
  12. 12.
    Duffy MJ. Do proteases play a role in cancer invasion and metastasis. Eur J Cancer Clin Oncol 1987; 23: 583–9.PubMedGoogle Scholar
  13. 13.
    Duffy MJ. Plasminogen activators and cancer. Blood Coag Fibrinol 1990; 1: 681–7.Google Scholar
  14. 14.
    Mullins DE, Rohrlich ST. The role of proteinases in cellular invasiveness. Biochim Biophys Acta 1983; 695: 177–214.PubMedGoogle Scholar
  15. 15.
    Goldberg GI, Wilhelm SM, Kronberger A et al. Human fibroblast collagenase: complete primary structure and homology to an oncogene transformation-induced rat protein. J Biol Chem 1986; 261: 6600–5.PubMedGoogle Scholar
  16. 16.
    Smyth Templeton M, Brown PD, Levy AT et al. Cloning and characterization of human tumor cell interstitial collagenase. Cancer Res 1990; 50: 5431–7.PubMedGoogle Scholar
  17. 17.
    Liotta L Tryggvason K Garbisa S et al. Partial purification and characterization of a neutral protease which cleaves type IV collagen. Biochemistry 1981; 20: 100–4.PubMedGoogle Scholar
  18. 18.
    Wilhelm SM, Collier IE, Marmer BL et al. SV40 transformed human lung fibroblasts secrete a 92 kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 1989; 264: 17213–21.PubMedGoogle Scholar
  19. 19.
    Kato Y, Ogawa K, Yamamoto S et al. A novel TIMP insensitive type IV collagen-degrading metal loproteinase from murine metastatic sarcoma cells. FEBS 1990; 268: 39–42.Google Scholar
  20. 20.
    Khokha R, Denhardt DT. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: a review of their role in tumorigenesis and tissue invasion. Inv Met 1989; 9: 391–405.Google Scholar
  21. 21.
    Stetler-Stevenson WG, Brown PD, Onisto M et al. Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J Biol Chem 1990; 265: 13933–8.PubMedGoogle Scholar
  22. 22.
    Dano K, Andreason PA, Grondahl-Hansen P et al. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1987; 44: 139–266.Google Scholar
  23. 23.
    Duffy MJ, O'Grady P. Plasminogen and cancer. Eur J Cancer Clin Oncol 1984; 20: 577–82.PubMedGoogle Scholar
  24. 24.
    Stopelli MP, Corti A, Soffientini A et al. Differentiation enhanced binding of the amino terminal fragment of human urokinase plasminogen activator to a specific receptor on 11937 monocytes. Proc Natl Acad Sci USA 1985; 82: 4939–43.PubMedGoogle Scholar
  25. 25.
    Vassali J-D, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator. J Cell Biol 1985; 100: 86–92.PubMedGoogle Scholar
  26. 26.
    Ossowski L.In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J Cell Biol 1988; 107: 2437–45.PubMedGoogle Scholar
  27. 27.
    Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: hormonally regulated serpins. Moll Cell Endocrinol 1990; 68: 1–19.Google Scholar
  28. 28.
    Astedt B, Lecander I, My T. The placental type Plasminogen activator inhibitor, PAI 2. Fibrinolysis 1987; 1: 203–8.Google Scholar
  29. 29.
    Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta 1985; 823: 35–65.PubMedGoogle Scholar
  30. 30.
    Sloane BF, Honn KV. Cysteine proteinases and metastasis. Cancer Met Rev 1984; 3: 249–63.Google Scholar
  31. 31.
    Mort JS, Recklies AD, Poole AR. Characterization of a thiol proteinase secreted by malignant human breast tumors. Biochem Biophys Acta 1980; 614: 134–43.PubMedGoogle Scholar
  32. 32.
    Pietras RJ, Roberts JA. Cathepsin B-like enzymes, subcellular distribution and properties in neoplastic and control cells from human ectocervix. J Biol Chem 1981;256: 8536–44.PubMedGoogle Scholar
  33. 33.
    Sloane BF, Rozhin J, Johnson K et al. Cathepsin B: association with plasma membrane in metastatic tumors. Proc Natl Acad Sci USA 1986; 83: 2483–7.PubMedGoogle Scholar
  34. 34.
    Keren Z, LeGrue SJ. Identification of cell surface cathepsin B-like activity on murine melanomas and fibrosarcomas: modulation by butanol extraction. Cancer Res 1988; 48: 1416–21.PubMedGoogle Scholar
  35. 35.
    Lah TT, Kokalj-Kunovar M, Turk V. Cysteine proteinase inhibitors in human cancerous tissues and fluids. Biol Chem Hoppe-Seyler 1990; 371 (Suppl): 199–203.PubMedGoogle Scholar
  36. 36.
    Zetter BR. The cellular basis of site specific tumor metastasis. N Eng J Med 1989; 322: 605–12.Google Scholar
  37. 37.
    Humphries MJ, Olden K, Yamada KM. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 1986; 233: 467–70.PubMedGoogle Scholar
  38. 38.
    Saiki I, Murata J, Iida J et al. The inhibition of murine lung metastasis by synthetic polypeptides [poly(Arg-Gly-Asp) and poly(Tyr-lie-Gly-Ser-Arg)] with a core sequence of cell adhesion molecules. Br J Cancer 1989; 59: 194–7.PubMedGoogle Scholar
  39. 39.
    Saiki I, Joyi I, Murata J et al. Inhibition of the metastasis of murine malignant melanoma cells by synthetic polymeric peptides containing core sequences of cell adhesive molecules. Cancer Res 1989; 49: 3815–22.PubMedGoogle Scholar
  40. 40.
    Peterson HI. Fibrinolysis and antifibrinolytic drugs in the growth and spread of tumors. Cancer Treat Rev 1977; 4: 213–7.PubMedGoogle Scholar
  41. 41.
    Tanaka N, Ogawa H, Tanaka K, Kinjo M, Kohga S. Effects of tranexamic acid and urokinase on hematogenous metastases of Lewis lung carcinoma in mice. Invasion Metastasis 1981; 1: 149–57.PubMedGoogle Scholar
  42. 42.
    Nelles JP, Schnebli HP. Are proteinase inhibitors potentially useful in tumor therapy? Invasion Metastasis 1982; 2: 113–24.PubMedGoogle Scholar
  43. 43.
    Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983; 35: 611–9.PubMedGoogle Scholar
  44. 44.
    Hearing VJ, Law L, Corti A, Appella E, Blasi F. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 1988; 48: 1270–8.PubMedGoogle Scholar
  45. 45.
    Hoyhtya M, Hujanen E, Turpeenniemi-Hajenen T. Modulation of type IV collagenase activity and invasive behaviour of metastatic melanoma (A205B) cellsin vitro by monoclonal antibodies to type IV collagenase. Int J Cancer 1990; 46: 282–6.PubMedGoogle Scholar
  46. 46.
    Baker MS, Bleakley P, Woodrow GC, Doe WF. Inhibition of cancer cell urokinase by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Cancer Res 1990; 50: 4676–84.PubMedGoogle Scholar
  47. 47.
    Schultz RM, Silberman S, Persky B et al. Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res 1988; 48: 5539–45.PubMedGoogle Scholar
  48. 48.
    Alvarez OA, Carmichael DF, DeClerck YA. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst 1990; 82: 589–95.PubMedGoogle Scholar
  49. 49.
    Yamada KM, Kennedy DW, Yamada SS et al. Monoclonal antibodies and synthetic peptide inhibitors of human tumor cell migration. Cancer Res 1990; 50: 4485–96.PubMedGoogle Scholar
  50. 50.
    Allolio B, Reincke M, Arlt W et al. Suramin for treatment of adrenocortical carcinoma. Lancet 1989; 2: 277.Google Scholar
  51. 51.
    Van Oosterom AT, DeSmedt EA, Denis LJ et al. Suramin for prostatic cancer: a phase 1/11 study in advanced extensively pretreated disease. Eur J Cancer 1990; 26: 422.PubMedGoogle Scholar
  52. 52.
    Zabrenetzky VS, Kohn EC, Roberts DD et al. Suramin inhibits laminin and thrombospondin-mediated melanoma cell adhesion and migration and binding of these adhesive proteins to sulfatide. Cancer Res 1990; 50: 5937–42.PubMedGoogle Scholar
  53. 53.
    Armand JP, Critkovic E. Suramin: a new therapeutic concept. Eur J Cancer 1990; 26: 417–9.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1992

Authors and Affiliations

  • M. J. Duffy
    • 1
  1. 1.Department of Nuclear MedicineSt. Vincent's HospitalDublin 4Ireland

Personalised recommendations